BioStock: SynAct Pharma secures patent for resomelagon in combination with MTX

The United States Patent and Trademark Office has issued a Notice of Allowance for SynAct Pharma’s patent application covering the use of resomelagon in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis. This indicates that the patent office intends to grant the patent, further strengthening the company’s patent portfolio.

Read the full article at biostock.se:

https://www.biostock.se/en/2025/04/synact-pharma-secures-patent-for-resomelagon-in-combination-with-mtx/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se